Grand Pharmaceutical climbs on progress of drug for prostate cancer

Grand Pharmaceutical

22/12/2025 04:35

** Shares of Grand Pharmaceutical Group 0512.HK climb 1.7% to HK$8.33, their highest level since Dec 11, and on course for a fourth straight session of gains

** Grand Pharmaceutical says its innovative investigational radionuclidedrug conjugate (RDC) TLX591-CDx for the diagnosis of prostate cancer, has achieved positive top-line results from the Phase III clinical trial in China and has met the primary clinical endpoint

** In addition, the company says its RDC product candidate TLX591 for the treatment of prostate cancer has been approved to

conduct an international multi-center Phase III clinical study in China

** YTD, stock up 73.3%, Hang Seng Biotech Index .HSBIO up 71.8%

 (Reporting by Donny Kwok)

 ((donny.kwok@thomsonreuters.com))